Innovation Pharmaceuticals (OTCMKTS:IPIX) & CureVac (NASDAQ:CVAC) Critical Analysis

CureVac (NASDAQ:CVAC) and Innovation Pharmaceuticals (OTCMKTS:IPIX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Insider and Institutional Ownership

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CureVac and Innovation Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$65.86 million	9.96	-$281.58 million	($1.33)	-2.20
Innovation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Innovation Pharmaceuticals has lower revenue, but higher earnings than CureVac.

Analyst Recommendations

This is a breakdown of current ratings and price targets for CureVac and Innovation Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0	3	1	0	2.25
Innovation Pharmaceuticals	0	0	0	0	N/A

CureVac presently has a consensus target price of $10.00, suggesting a potential upside of 240.14%. Given CureVac’s higher probable upside, equities research analysts clearly believe CureVac is more favorable than Innovation Pharmaceuticals.

Profitability

This table compares CureVac and Innovation Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	-422.66%	-57.18%	-38.60%
Innovation Pharmaceuticals	N/A	N/A	N/A

Summary

CureVac beats Innovation Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

About Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.